---

42. Neonatal blood rheological parameters at delivery in healthy neonates and in those with morbidities.
2013 Mar 26. [in press] PMID: 23532177. Clin Hemorheol Microcirc. 0
A.A. Soliman, R. Csorba, P. Tsikouras, C. Wieg, H. Harnack, G.-F.v. Tempelhoff.

---

41. Pregnancies and their obstetric outcome in two selected age groups of teenage women in Greece.
2012;25:1606-11. J Matern Fetal Neonatal Med. 1.518
P. Tsikouras, A. Dafopoulos, G. Trypsianis, N. Vrachnis, S. Bouchlariotou, S.A.Liatsikos, K. Dafopoulos, G. Maroulis, G. Galazios G, A.T. Teichmann, G.-F.v. Tempelhoff.

---

40. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer.
2012;18:159-65. Clin Appl Thromb Hemost. 1.016
S.K. Haas, M. Freund, D. Heigener, L. Heilmann, B. Kemkes-Matthe, G.-F.v. Tempelhoff , N. Melzer, A.K. Kakkar, TOPIC Investigators.

---

39. Blood rheology at term in women with normal and complicated pregnancy.
2009;42:127-39. Clin Hemorheol Microcirc. 3.398
G.-F.v. Tempelhoff, L. Heilmann, E. Velten, P. Freund, J. Koscielny.

---

38. Mean maternal 2nd trimester hemoglobin-concentration and outcome of pregnancy – A population based Study.
2008;14:19-28. Clin Appl Thromb Hemost. 1.016
G.-F.v. Tempelhoff, L. Heilmann, L. Rudig, C. Wildt, K. Pollow, G. Hommel, J. Koscielny.

---

37. Preoperative identification of patients with impaired (primary) hemostasis - a practical concept.
2007;27:177-84. Hamostaseologie. 1.190
J. Koscielny, S. Ziemer, H. Radtke, M. Schmutzler, H. Kiesewetter, A. Salama, G.-F v. Tempelhoff.

---

36. More on: platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function.
2006;4:1426-7. J Thromb Haemost. 6.081
J. Koscielny, H. Kiesewetter, G.-F.v. Tempelhoff.

---

35. Monitoring of rheological variables during post operative high dose brachytherapy for uterine cancer.
2004;10:239-48. Clin Appl Thromb Hemost. 1.332
G.-F.v. Tempelhoff, L. Heilmann, K. Pollow, G. Hommel.

---

34. A practical concept for preoperative management of patients with impaired primary hemostasis.
2004;10:155-66. Clin Appl Thromb Hemost. 1.332
J. Koscielny ,G.-F.v. Tempelhoff, S. Ziemer, H. Radtke, M. Schmutzler, P. Sinha, A. Salama.

---

33. ProC® Global Assay in the evaluation of women with history of severe preeclampsia or HELLP Syndrome.
2002;8:319-24. Clin Appl Thromb Hemost. 1.332
L. Heilmann, G.-F.v. Tempelhoff, K. Pollow.

---

32. Thrombosis - A clue of poor prognosis in primary non-metastatic Breast Cancer.
2002;73:275-7. Breast Cancer Res Treat. 4.431
G.-F.v. Tempelhoff, L. Heilmann, G. Hommel.

---

31. Soluble Urokinase Plasminogen Activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological cancer.
2001;82:523-31. Gynecol Oncol. 3.888
R. Riisbro, R.W. Stephens, N. Brünner, L.J. Christensen, H.J. Nielsen, L. Heilmann, G.-F. v. Tempelhoff.

---

30. Tumor Hypoxia, the physiological link between Trousseaus’s Syndrome (Carcinoma induced Coagulopathy) and Metastasis.
2001;61:7697-8. Cancer Res. 7.856
G.-F.v. Tempelhoff, L. Heilmann, G. Hommel.

---

29. The role of intravenous volume expansion in moderate pre-eclampsia.
2001;25:83-9. Clin Hemorheol Microcirc. 3.398
L. Heilmann, S. Gerhold, G.-F.v. Tempelhoff, K. Pollow.

---

28. The influence of antiphospholipid antibodies on the pregnancy outcome of patients with recurrent spontaneous abortion.
2001;7:281-5. Clin Appl Thromb Hemost. 1.332
L. Heilmann, G.-F.v. Tempelhoff, S. Kuse.

---